|
01.10.2014 13:44:06
|
Isis Pharma Earns $1.5 Mln From GSK For The Advancement Of ISIS-GSK4 Rx
(RTTNews) - Isis Pharmaceuticals Inc. (ISIS) announced that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4Rx to treat an undisclosed ocular disease.
"Our collaboration with GSK has been very productive resulting in four drugs in development. We look forward to advancing ISIS-GSK4Rx into clinical development and providing more information on the target and disease opportunity, which we are very excited about," said Lynne Parshall, chief operating officer at Isis.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ISIS Pharmaceuticals Inc.mehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu ISIS Pharmaceuticals Inc.mehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.